AGEN Stock Analysis: ASCO Hype, Cash Risk

AGEN stock analysis featured image with market cap, revenue, and ASCO catalyst

Agenus is a real biotech catalyst trade, not a hidden value stock. At roughly a $144 million market cap, with Phase 2 melanoma data due at ASCO on May 31 and a first-quarter corporate update scheduled for May 11, the setup is obvious: if the botensilimab story keeps getting cleaner, the stock can move fast. …

Read more

Analyzing Zynex’s Growth Potential: A Comprehensive Stock Analysis

Zynex is a medical technology company that specializes in the design, manufacture, and marketing of non-invasive medical devices for pain management and rehabilitation. The company was founded in 1996 and is headquartered in Lone Tree, Colorado. Zynex’s products are used by healthcare professionals and patients to manage pain, improve mobility, and enhance overall quality of …

Read more